Transcriptomics Sequencing and analysis in Liver Spheroids
Closed Solicitation Posted
- Solicitation number
- 75N95025Q00040
- Agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- Q301 Reference Laboratory Testing
- Place of performance
- Rockville, Maryland 20850, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The National Center for Advancing Translational Sciences (NCATS), part of the National Institute on Drug Abuse (NIDA) within the Department of Health and Human Services, is seeking technical support to evaluate the safety and acute liver toxicity of candidate antisense oligonucleotides (ASOs) using a 3D liver microtissue platform. The objective is to generate proof-of-concept data to assess the ability of this platform to predict the hepatoxicity of individual ASOs, which will help develop a more cost-effective, faster, and higher throughput screening method compared to existing cell-based assays. NCATS is requesting a contract to analyze the gene expression in liver toxicity associated with ASOs in previously tested animal models, with the goal of creating a predictive model for the safety and acute toxicity of candidate ASO therapies.
This non-competitive solicitation is being conducted under simplified acquisition procedures, with responses due by 3:00 PM ET on November 22, 2024. NCATS will provide 8 hepatotoxic and 8 safe ASOs for evaluation, and the anticipated period of performance is 8 weeks. The contractor will test the ASOs at two concentrations and two time points, with 7 biological replicates, and provide a full report with raw data and explanations at the end of the project.
Notice text
The National Center for Advancing Translational Sciences (NCATS) requires transcriptomics sequencing and analysis in liver spheroids. This requisition is requesting a contract to evaluate the RNA expression in liver toxicity associated with the systemic administration of antisense oligonucleotides (ASOs) in previously tested human, rat and mouse animal models. The project's phase one goal is to develop a predictive model of candidate ASO therapies' safety and acute toxicity. NCATS is seeking technical support to evaluate the safety and acute liver toxicity of candidate ASOs by checking the gene expression. The results from these studies, in conjunction with existing cell-based assays, will help better predict the safety of future candidate ASOs intended for clinical use. The objective of this contract is to generate proof-of-concept data for evaluating the ability of the 3D liver microtissue platform to predict the hepatoxicity of individual ASOs. If successful, this will represent a new means to screen ASOs for this type of toxicity that is cheaper, faster, and has high throughput. NCATS is seeking technical support to evaluate the safety and acute liver toxicity of candidate ASOs by checking the gene expression. The results from these studies, in conjunction with existing cell-based assays, will help better predict the safety of future candidate ASOs intended for clinical use.
Files
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity